These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 23063168)

  • 1. No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design.
    Lysgaard C; Nielsen MS; Christensen JH; Lundbye-Christensen S; Riahi S; Schmidt EB
    Prostaglandins Leukot Essent Fatty Acids; 2012 Dec; 87(6):185-8. PubMed ID: 23063168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery.
    Riahi S; Schmidt EB; Amanavicius N; Karmisholt J; Jensen HS; Christoffersen RP; Niebuhr U; Christensen JH; Toft E
    Int J Cardiol; 2006 Aug; 111(3):436-41. PubMed ID: 16290290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery.
    Chello M; Patti G; Candura D; Mastrobuoni S; Di Sciascio G; Agrò F; Carassiti M; Covino E
    Crit Care Med; 2006 Mar; 34(3):660-7. PubMed ID: 16505650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
    Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.
    Neilipovitz DT; Bryson GL; Taljaard M
    Can J Anaesth; 2012 Jun; 59(6):527-37. PubMed ID: 22528165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity.
    Antoniades C; Bakogiannis C; Tousoulis D; Reilly S; Zhang MH; Paschalis A; Antonopoulos AS; Demosthenous M; Miliou A; Psarros C; Marinou K; Sfyras N; Economopoulos G; Casadei B; Channon KM; Stefanadis C
    Circulation; 2010 Sep; 122(11 Suppl):S66-73. PubMed ID: 20837928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
    Gómez-Hernández A; Sánchez-Galán E; Ortego M; Martín-Ventura JL; Blanco-Colio LM; Tarín-Vicente N; Jiménez-Nacher JJ; López-Bescos L; Egido J; Tuñón J
    Am J Cardiol; 2008 Jul; 102(1):12-8. PubMed ID: 18572029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
    Rifaie O; Zahran A; Nammas W
    Anadolu Kardiyol Derg; 2012 Mar; 12(2):90-6. PubMed ID: 22281786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.
    Dogra GK; Watts GF; Chan DC; Stanton K
    Diabet Med; 2005 Mar; 22(3):239-42. PubMed ID: 15717868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.